"Anthos' Safer Blood Thinner Reduces Bleeding Risk in Race for Anticoagulant Development"

Anthos Therapeutics' investigational anticoagulant has shown promising results in a mid-stage safety study, significantly reducing the risk of bleeding compared to Xarelto. This new class of anticoagulants aims to provide patients with a safer option for preventing stroke and blood clots, addressing one of the major concerns associated with current blood thinners.